These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 12060153)
61. Fluoro-2-deoxy-glucose positron emission tomography in oncology: are we there yet? Khafagi FA Intern Med J; 2001; 31(1):3-4. PubMed ID: 11478354 [No Abstract] [Full Text] [Related]
62. Positron emission tomography imaging in evaluation of cancer patients. Kumar R; Bhargava P; Bozkurt MF; Zhuang H; Potenta S; Alavi A Indian J Cancer; 2003; 40(3):87-100. PubMed ID: 14716112 [TBL] [Abstract][Full Text] [Related]
63. Positron emission tomography with fluorodeoxyglucose to evaluate tumor response and control after radiation therapy. Chaiken L; Rege S; Hoh C; Choi Y; Jabour B; Juillard G; Hawkins R; Parker R Int J Radiat Oncol Biol Phys; 1993 Sep; 27(2):455-64. PubMed ID: 8407422 [TBL] [Abstract][Full Text] [Related]
64. PET and PET-CT. State of the art and future prospects. Fanti S; Franchi R; Battista G; Monetti N; Canini R Radiol Med; 2005; 110(1-2):1-15. PubMed ID: 16163136 [TBL] [Abstract][Full Text] [Related]
65. Improved detection of second primary cancer using integrated [18F] fluorodeoxyglucose positron emission tomography and computed tomography for initial tumor staging. Choi JY; Lee KS; Kwon OJ; Shim YM; Baek CH; Park K; Lee KH; Kim BT J Clin Oncol; 2005 Oct; 23(30):7654-9. PubMed ID: 16234527 [TBL] [Abstract][Full Text] [Related]
66. The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer. Flamen P; Lerut A; Van Cutsem E; Cambier JP; Maes A; De Wever W; Peeters M; De Leyn P; Van Raemdonck D; Mortelmans L J Thorac Cardiovasc Surg; 2000 Dec; 120(6):1085-92. PubMed ID: 11088030 [TBL] [Abstract][Full Text] [Related]
67. [18F FDG PET- applications in oncology]. Răileanu I; Rusu V; Stefănescu C; Cinotti L Rev Med Chir Soc Med Nat Iasi; 2001; 105(4):638-45. PubMed ID: 12092212 [TBL] [Abstract][Full Text] [Related]
68. Positron-emission tomography for head and neck cancer. Greven KM Semin Radiat Oncol; 2004 Apr; 14(2):121-9. PubMed ID: 15095258 [TBL] [Abstract][Full Text] [Related]
69. Positron-emission tomographic imaging of cancer: glucose metabolism and beyond. Mankoff DA; Bellon JR Semin Radiat Oncol; 2001 Jan; 11(1):16-27. PubMed ID: 11146039 [TBL] [Abstract][Full Text] [Related]
70. Update on advances in molecular PET in urological oncology. Kitajima K; Yamamoto S; Fukushima K; Minamimoto R; Kamai T; Jadvar H Jpn J Radiol; 2016 Jul; 34(7):470-85. PubMed ID: 27222021 [TBL] [Abstract][Full Text] [Related]
71. 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography scanning affects surgical management in selected patients with high-risk, operable breast carcinoma. Port ER; Yeung H; Gonen M; Liberman L; Caravelli J; Borgen P; Larson S Ann Surg Oncol; 2006 May; 13(5):677-84. PubMed ID: 16538409 [TBL] [Abstract][Full Text] [Related]
72. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas. Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094 [TBL] [Abstract][Full Text] [Related]
73. Clinical applications of positron emission tomography-computed tomography in oncology. Kumar R; Halanaik D; Malhotra A Indian J Cancer; 2010; 47(2):100-19. PubMed ID: 20448371 [TBL] [Abstract][Full Text] [Related]
74. [The contribution of PET to radiation treatment planning]. Belkacémi Y; Lartigau E; Kerrou K; Carpentier P; Taïeb S; Giraud P Bull Cancer; 2007 Jan; 94(1):99-108. PubMed ID: 17237010 [TBL] [Abstract][Full Text] [Related]
75. The clinical application of positron emission tomography to colorectal cancer management. Arulampalam TH; Costa DC; Bomanji JB; Ell PJ Q J Nucl Med; 2001 Sep; 45(3):215-30. PubMed ID: 11788814 [TBL] [Abstract][Full Text] [Related]
76. Clinical positron emission tomography imaging--current applications. Goh AS; Ng DC Ann Acad Med Singap; 2003 Jul; 32(4):507-17. PubMed ID: 12968557 [TBL] [Abstract][Full Text] [Related]
77. The stage is set for the diffusion of positron emission tomography (PET) in oncology. Morris JG Med J Aust; 1999 Nov; 171(10):527-8. PubMed ID: 10816702 [No Abstract] [Full Text] [Related]
78. Advances in positron tomography for oncology. Budinger TF; Brennan KM; Moses WW; Derenzo SE Nucl Med Biol; 1996 Aug; 23(6):659-67. PubMed ID: 8940706 [TBL] [Abstract][Full Text] [Related]
79. The role of positron emission tomography in oncology and other whole-body applications. Hawkins RA; Hoh C; Glaspy J; Choi Y; Dahlbom M; Rege S; Messa C; Nietszche E; Hoffman E; Seeger L Semin Nucl Med; 1992 Oct; 22(4):268-84. PubMed ID: 1439872 [TBL] [Abstract][Full Text] [Related]
80. Use of positron emission tomography in anticancer drug development. Aboagye EO; Price PM Invest New Drugs; 2003 May; 21(2):169-81. PubMed ID: 12889738 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]